What the trial was testing
The DESSOLVE III enrolled 1,398 patients with coronary artery disease. The study was sponsored by ECRI bv and tracked outcomes across the full group of patients who matched the trial's eligibility profile.
Researchers followed patients through treatment and into recovery, tracking the outcomes that mattered most for the disease being studied.
What the results showed
Equal results — 5.8% vs. 6.5% major heart events at one year.
The Lancet · 2018 · NCT02385279
These findings — that major heart events at 12 months — MiStent matched Xience in performance — were published in the The Lancet and represent the headline result of the study.
Researchers tracked outcomes across 1,398 patients enrolled in the trial. The result was consistent enough across the group that the team felt confident reporting it.
What this means for patients
For patients with coronary artery disease, this result changes the calculus on what to ask their care team about. Whether it changes day-to-day care depends on factors like disease subtype, prior treatments, and where the patient is in their care journey.
What you can do now
The Xience stent is FDA-approved and widely used in the U.S. The MiStent has had limited U.S. availability and is primarily used in Europe. Both are reasonable choices. Ask your cardiologist who places stents about which one they recommend for your case.
Eligibility for the treatments mentioned above depends on specific test results and clinical history. Bring this summary, the trial name, and your most recent labs or pathology report to your next visit.
Open coronary artery disease trials
Digital Long-term Follow-up of Patients With Coronary Artery Disease
The need for better follow-up of AMI patients combined with recent developments in the digital area prompted the Department of Cardiology (HJE) at Oslo University Hospital (OUS) Ullevål, in collaboration with the Department of Digital Health Research (DIG) at OUS to develop a digital solution for long-term follow-up after AMI. The overall goal of the digital solution is to increase knowledge and awareness about important lifestyle measures and CV risk factors in patients who have survived an AMI, and to make it easy for the patients to monitor their own risk factors and attainment of treatment goals during long-term follow-up. Further, the HeartCheck seeks to provide guidance to ensure medication adherence. In this project, we study whether this newly developed app (HeartCheck), through education, regular reminders and easily understandable goals for secondary prevention, can improve risk factor control and drug adherence during long-term follow-up after AMI. A randomized controlled trial (RCT) is the chosen study design, being the gold standard for testing effectiveness of interventions.
ULTIMATE Study (Carotid Ultrasound Vs CT Coronary Calcium Scoring to Reclassify Symptomatic Patients With Chronic Coronary Syndrome)
* Chest pain is one of the most common symptoms of heart disease. This could be due to narrowing in heart's blood vessels, which needs to be investigated. * Currently, people with a low risk of narrowing of heart vessels usually have a CT scan of the heart first. This scan is good at identifying those who do not have significant narrowing. However, the scan has some drawbacks, such as exposure to a small amount of radiation. * We are exploring if ultrasound of the neck vessels might give us similar kind of information as the CT scan. * You will be asked to attend the hospital for one visit to have an ultrasound scan of your neck. * The findings of your neck vessels will be compared with the CT scan of your heart vessels to see if there is a similarity.